Annexon jumps as neuromuscular disease drug succeeds in late-stage trial

Annexon

04/06/2024 12:29

** Shares of drug developer Annexon  ANNX.O  rise ~29.3% to
$5.92
    ** Co says its drug ANX005 met the main goal of showing
significant improvement in the motor function of patients with
Guillain-Barré syndrome (GBS) during a late-stage trial
    ** GBS is a rare condition where the body's immune system
damages nerves, causing muscle weakness and sometimes paralysis
    ** ANNX says the drug showed improvements in secondary goals
such as muscle strength and nerve damage
    ** Up to last close, stock mostly flat YTD

    

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))